|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
42,345,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vera Therapeutics is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Co.'s primary product candidate, atacicept, a self-administered fusion protein that blocks both blisibimod and APRIL, is being evaluated for the treatment of immunoglobulin A nephropathy in a global, randomized, double-blind, placebo-controlled clinical trial. Co. has obtained worldwide, exclusive development and commercial rights from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for MAU868, a potentially monoclonal antibody to treat BK viremia infections.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
161,290 |
614,507 |
4,957,633 |
Total Buy Value |
$0 |
$4,999,990 |
$11,881,994 |
$42,392,668 |
Total People Bought |
0 |
1 |
3 |
8 |
Total Buy Transactions |
0 |
1 |
3 |
27 |
Total Shares Sold |
989,487 |
2,039,487 |
2,047,677 |
2,318,381 |
Total Sell Value |
$40,322,300 |
$59,222,300 |
$59,358,712 |
$64,660,810 |
Total People Sold |
3 |
4 |
7 |
8 |
Total Sell Transactions |
8 |
9 |
12 |
42 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Seidenberg Beth C |
Director |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
1,343,152 |
1,343,152 |
|
- |
|
Emster Kurt Von |
Director |
|
2021-05-18 |
4 |
B |
$11.00 |
$8,499,997 |
I/I |
772,727 |
2,960,231 |
2.1 |
- |
|
Emster Kurt Von |
Director |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,187,504 |
2,187,504 |
|
- |
|
Abingworth Llp |
10% Owner |
|
2021-05-18 |
4 |
B |
$11.00 |
$8,499,997 |
I/I |
772,727 |
2,960,231 |
1.5 |
- |
|
Abingworth Llp |
10% Owner |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,187,504 |
2,187,504 |
|
- |
|
Cheng Andrew |
Director |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
17,488 |
17,488 |
|
- |
|
Katabi Maha |
Director |
|
2021-05-18 |
4 |
B |
$11.00 |
$7,999,992 |
I/I |
727,272 |
2,914,776 |
2.25 |
- |
|
Katabi Maha |
Director |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,187,504 |
2,187,504 |
|
- |
|
Enright Patrick G |
Director |
|
2021-05-18 |
4 |
B |
$11.00 |
$9,999,990 |
I/I |
909,090 |
3,096,594 |
2.25 |
- |
|
Enright Patrick G |
Director |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,187,504 |
2,187,504 |
|
- |
|
Powell Michael |
10% Owner |
|
2021-05-18 |
4 |
B |
$11.00 |
$7,999,992 |
D/D |
727,272 |
2,914,776 |
2.45 |
- |
|
Powell Michael |
10% Owner |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,187,504 |
2,187,504 |
|
- |
|
Emster Kurt Von |
Director |
|
2021-05-17 |
4 |
B |
$12.04 |
$214,656 |
D/D |
17,828 |
17,828 |
2.39 |
- |
|
138 Records found
|
|
Page 6 of 6 |
|
|